Synthetic biology firm Asimov has introduced a new manufacturing platform aimed at improving the scalability and consistency of adeno-associated virus (AAV) production for gene therapies. The company’s AAV Edge Stable Producer System is designed to overcome limitations associated with transient transfection-based methods, which remain the industry standard despite cost and quality concerns. Asimov’s system integrates all essential viral genes into the genome of HEK293 cells, creating high-tit...